6-bromo-8-(4-[3H]methoxybenzamido)-4-oxo-4H-chromene-2- carboxylic acid: A powerful tool for studying orphan G protein-coupled receptor GPR35

Journal of Medicinal Chemistry

Volumn 56, Issue 17, 2013, Pages 7084-7099

  Thimm, Dominik ^a   Funke, Mario ^a   Meyer, Anne ^a   Müller, Christa E ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 BROMO 8 (2 FLUORO 4 METHOXYBENZAMIDO) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID; 6 BROMO 8 (2,6 DIFLUORO 4 METHOXYBENZAMIDO) 4 OXO 4H ACID; 6 BROMO 8 (2,6 DIFLUORO 4 METHOXYBENZAMIDO) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID; 6 BROMO 8 (3 FLUORO 4 METHOXYBENZAMIDO) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID; 6 BROMO 8 (4 METHOXYBENZAMIDO) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID; 6 BROMO 8 BENZAMIDOCHROMEN 4 ONE 2 CARBOXYLIC ACID; BENZAMIDE DERIVATIVE; BETA ARRESTIN; CARBOXYLIC ACID DERIVATIVE; CROMOGLYCATE DISODIUM; DICOUMAROL; EMBONIC ACID; FUROSEMIDE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 35; KYNURENIC ACID; LIGAND; LUCIFERIN; NIFLUMIC ACID; PSB 13253; RADIOLIGAND; TRITIUM; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CHEMICAL ANALYSIS; CHEMICAL REACTION KINETICS; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; HYDROLYSIS; ISOTOPE LABELING; METHYLATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; SUBSTITUTION REACTION;

CARBOXYLIC ACIDS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; RADIOLIGAND ASSAY; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884217739     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4009373     Document Type: Article

References (70)

1. O'Dowd, B. F.; Nguyen, T.; Marchese, A.; Cheng, R.; Lynch, K. R.; Heng, H. H.; Kolakowski, L. F., Jr.; George, S. R. Discovery of three novel G-protein-coupled receptor genes Genomics 1998, 47, 310-313
2. Wang, J.; Simonavicius, N.; Wu, X.; Swaminath, G.; Reagan, J.; Tian, H.; Ling, L. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35 J. Biol. Chem. 2006, 281, 22021-22028
3. Deng, H.; Hu, H.; Fang, Y. Multiple tyrosine metabolites are GPR35 agonists Sci. Rep. 2012, 2, 373
4. Oka, S.; Ota, R.; Shima, M.; Yamashita, A.; Sugiura, T. GPR35 is a novel lysophosphatidic acid receptor Biochem. Biophys. Res. Commun. 2010, 395, 232-237
5. Milligan, G. Orthologue selectivity and ligand bias: translating the pharmacology of GPR35 Trends Pharmacol. Sci. 2011, 32, 317-325
6. Pertwee, R. G.; Howlett, A. C.; Abood, M. E.; Alexander, S. P.; Di Marzo, V.; Elphick, M. R.; Greasley, P. J.; Hansen, H. S.; Kunos, G.; Mackie, K.; Mechoulam, R.; Ross, R. A. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2) Pharmacol. Rev. 2010, 62, 588-631
7. Okumura, S.; Baba, H.; Kumada, T.; Nanmoku, K.; Nakajima, H.; Nakane, Y.; Hioki, K.; Ikenaka, K. Cloning of a G-protein-coupled receptor that shows an activity to transform NIH3T3 cells and is expressed in gastric cancer cells Cancer Sci. 2004, 95, 131-135
8. Fallarini, S.; Magliulo, L.; Paoletti, T.; de Lalla, C.; Lombardi, G. Expression of functional GPR35 in human iNKT cells Biochem. Biophys. Res. Commun. 2010, 398, 420-425
9. Cosi, C.; Mannaioni, G.; Cozzi, A.; Carla, V.; Sili, M.; Cavone, L.; Maratea, D.; Moroni, F. G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: studies on the antinociceptive effects of kynurenic acid and zaprinast Neuropharmacology 2011, 60, 1227-1231
10. Ohshiro, H.; Tonai-Kachi, H.; Ichikawa, K. GPR35 is a functional receptor in rat dorsal root ganglion neurons Biochem. Biophys. Res. Commun. 2008, 365, 344-348
11. Taniguchi, Y.; Tonai-Kachi, H.; Shinjo, K. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35 FEBS Lett. 2006, 580, 5003-5008
12. Min, K. D.; Asakura, M.; Liao, Y.; Nakamaru, K.; Okazaki, H.; Takahashi, T.; Fujimoto, K.; Ito, S.; Takahashi, A.; Asanuma, H.; Yamazaki, S.; Minamino, T.; Sanada, S.; Seguchi, O.; Nakano, A.; Ando, Y.; Otsuka, T.; Furukawa, H.; Isomura, T.; Takashima, S.; Mochizuki, N.; Kitakaze, M. Identification of genes related to heart failure using global gene expression profiling of human failing myocardium Biochem. Biophys. Res. Commun. 2010, 393, 55-60
13. Yoon, M. H.; Choi, J. I.; Bae, H. B.; Jeong, S. W.; Chung, S. S.; Yoo, K. Y.; Jeong, C. Y.; Kim, S. J.; Chung, S. T.; Kim, C. M. Lack of the nitric oxide-cyclic GMP-potassium channel pathway for the antinociceptive effect of intrathecal zaprinast in a rat formalin test Neurosci. Lett. 2005, 390, 114-117
14. Barth, M. C.; Ahluwalia, N.; Anderson, T. J.; Hardy, G. J.; Sinha, S.; Alvarez-Cardona, J. A.; Pruitt, I. E.; Rhee, E. P.; Colvin, R. A.; Gerszten, R. E. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions J. Biol. Chem. 2009, 284, 19189-19195
15. Vander Molen, J.; Frisse, L. M.; Fullerton, S. M.; Qian, Y.; Del Bosque-Plata, L.; Hudson, R. R.; Di Rienzo, A. Population genetics of CAPN10 and GPR35: implications for the evolution of type 2 diabetes variants Am. J. Hum. Genet. 2005, 76, 548-560
16. Sun, Y. V.; Bielak, L. F.; Peyser, P. A.; Turner, S. T.; Sheedy, P. F., 2nd; Boerwinkle, E.; Kardia, S. L. Application of machine learning algorithms to predict coronary artery calcification with a sibship-based design Genet. Epidemiol. 2008, 32, 350-360
17. Deng, H.; Hu, H.; He, M.; Hu, J.; Niu, W.; Ferrie, A. M.; Fang, Y. Discovery of 2-(4-methylfuran-2(5 H)-ylidene)malononitrile and thieno[3,2- b ]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists J. Med. Chem. 2011, 54, 7385-7396
18. Hu, H.; Deng, H.; Fang, Y. Label-free phenotypic profiling identified D-luciferin as a GPR35 agonist PLoS One 2012, 7, e34934
19. α13 Biochem. J. 2010, 432, 451-459
20. Jenkins, L.; Harries, N.; Lappin, J. E.; MacKenzie, A. E.; Neetoo-Isseljee, Z.; Southern, C.; McIver, E. G.; Nicklin, S. A.; Taylor, D. L.; Milligan, G. Antagonists of GPR35 display high species ortholog selectivity and varying modes of action J. Pharmacol. Exp. Ther. 2012, 343, 683-695
21. Neetoo-Isseljee, Z.; Mackenzie, A. E.; Southern, C.; Jerman, J.; McIver, E. G.; Harries, N.; Taylor, D. L.; Milligan, G. High-throughput identification and characterization of novel, species-selective GPR35 agonists J. Pharmacol. Exp. Ther. 2013, 344, 568-578
22. Taniguchi, Y.; Tonai-Kachi, H.; Shinjo, K. 5-Nitro-2-(3- phenylpropylamino)benzoic acid is a GPR35 agonist Pharmacology 2008, 82, 245-249
23. Yang, Y.; Fu, A.; Wu, X.; Reagan, J. D. GPR35 is a target of the loop diuretic drugs bumetanide and furosemide Pharmacology 2012, 89, 13-17
24. Yang, Y.; Lu, J. Y.; Wu, X.; Summer, S.; Whoriskey, J.; Saris, C.; Reagan, J. D. G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium Pharmacology 2010, 86, 1-5
25. Zhao, P.; Sharir, H.; Kapur, A.; Cowan, A.; Geller, E. B.; Adler, M. W.; Seltzman, H. H.; Reggio, P. H.; Heynen-Genel, S.; Sauer, M.; Chung, T. D.; Bai, Y.; Chen, W.; Caron, M. G.; Barak, L. S.; Abood, M. E. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity Mol. Pharmacol. 2010, 78, 560-568
26. Funke, M.; Thimm, D.; Schiedel, A. C.; Müller, C. E. 8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35 J. Med. Chem. 2013, 56, 5182-5197
27. 13 and β-arrestin-2 Br. J. Pharmacol. 2011, 162, 733-748
28. Heynen-Genel, S.; Dahl, R.; Shi, S.; Sauer, M.; Hariharan, S.; Sergienko, E.; Dad, S.; Chung, T. D. Y.; Stonich, D.; Su, Y.; Caron, M.; Zhao, P.; Abood, M. E.; Barak, L. S. Selective GPR35 antagonists-probes 1 & 2. Probe Reports from the NIH Molecular Libraries Program [Online]; National Center for Biotechnology Information: Bethesda, MD, updated Oct 4, 2010. http://www.ncbi.nlm.nih.gov/books/NBK50703/.
29. Seifert, R.; Schneider, E. H.; Dove, S.; Brunskole, I.; Neumann, D.; Strasser, A.; Buschauer, A. Paradoxical stimulatory effects of the "standard" histamine H4-receptor antagonist JNJ7777120: the H4 receptor joins the club of 7 transmembrane domain receptors exhibiting functional selectivity Mol. Pharmacol. 2011, 79, 631-638
30. 3H]MRE 2029-F20 Mol. Pharmacol. 2005, 67, 2137-2147
31. 2B receptor Biochemistry 2013, 52, 726-740
32. Thor, D.; Schulz, A.; Hermsdorf, T.; Schoneberg, T. Generation of an agonistic binding site for blockers of the M(3) muscarinic acetylcholine receptor Biochem. J. 2008, 412, 103-112
33. 2aR as a template for study. Current Protocols in Protein Science; Wiley: New York, 2012; Chapter 29, Unit 29.3, p 23.
34. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human κ-opioid receptor in complex with JDTic Nature 2012, 485, 327-332
35. Haga, K.; Kruse, A. C.; Asada, H.; Yurugi-Kobayashi, T.; Shiroishi, M.; Zhang, C.; Weis, W. I.; Okada, T.; Kobilka, B. K.; Haga, T.; Kobayashi, T. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist Nature 2012, 482, 547-551
36. Sinhababu, A. K.; Kawase, M.; Borchardt, R. T. tert -Butyldimethylsilyl ethers of phenols-their one-step conversion to benzyl or methyl ethers and utility in regioselective ortho lithiation Tetrahedron Lett. 1987, 28, 4139-4142
37. Aquino, C. J.; Dickson, H.; Peat, A. J. Chemical compounds. WO2008/157330A1, 20081224, 2008.
38. Stern, A. J.; Swenton, J. S. The unusually slow hydrolysis rate of silyl methyl ketals in benzoquinone systems. The question of siloxy stabilization of an adjacent positive charge and stereoelectronic effects on ketal hydrolysis J. Org. Chem. 1989, 54, 2953-2958
39. de Jong, A. P. J. M.; Elema, J.; van de Berg, B. J. T. Gas-chromatography mass-spectrometry of tert-butyldimethylsilyl derivatives of organic acids Biomed. Mass Spectrom. 1980, 7, 359-364
40. Giri, B. P.; Dagli, D.; Singh, P. New ultra-sensitive chemiluminescent substrates for enzymes and their conjugates. WO2006/073424A2, 20060713, 2006.
41. Raposo, C.; Crego, M.; Mussons, M. L.; Caballero, M. C.; Moran, J. R. Readily available chromenone receptors for carboxylates Tetrahedron Lett. 1994, 35, 3409-3410
42. Hibino, H.; Ohtsuka, S.; Miyamoto, Y.; Yoshida, T.; Okumoto, I. Process for producing chromone compound. WO2003080555, 20031002, 2003.
43. Nakai, H.; Konno, M.; Kosuge, S.; Sakuyama, S.; Toda, M.; Arai, Y.; Obata, T.; Katsube, N.; Miyamoto, T.; Okegawa, T.; Kawasaki, A. New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships J. Med. Chem. 1988, 31, 84-91
44. Anderluh, M.; Marc, G.; Dolenc, M. S. Convenient synthesis and reactivity of ethyl 8-amino-6-methyl-2,3-dihydro-4 H -1-benzopyran-2-carboxylate Synth. Commun. 2005, 35, 1461-1470
45. Burdeska, K. 4,6-Disubstituted 2-aminophenols Synthesis 1982, 11, 940-942
46. Raposo, C.; Luengo, A.; Almaraz, M.; Martin, M.; Mussons, M. L.; Caballero, M. C.; Moran, J. R. Malonic acid receptors with decarboxylative activity Tetrahedron 1996, 52, 12323-12332
47. 1 receptors in brain membranes Mol. Pharmacol. 1982, 21, 329-335
48. Mong, S.; Wu, H. L.; Hogaboom, G. K.; Clark, M. A.; Crooke, S. T. Characterization of the leukotriene D4 receptor in guinea-pig lung Eur. J. Pharmacol. 1984, 102, 1-11
49. 3H-UK-14, 304: regulation by Gpp(NH)p and cations Naunyn-Schmiedebergs Arch. Pharmakol. 1987, 336, 48-59
50. Slipetz, D. M.; O'Neill, G. P.; Favreau, L.; Dufresne, C.; Gallant, M.; Gareau, Y.; Guay, D.; Labelle, M.; Metters, K. M. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase Mol. Pharmacol. 1995, 48, 352-361
51. 3H]NECA in rat striatal membranes Mol. Pharmacol. 1986, 29, 331-346
52. Chin, C. N.; Lucas-Lenard, J.; Abadji, V.; Kendall, D. A. Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1 J. Neurochem. 1998, 70, 366-373
53. Igel, P.; Geyer, R.; Strasser, A.; Dove, S.; Seifert, R.; Buschauer, A. Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists J. Med. Chem. 2009, 52, 6297-6313
54. Tunaru, S.; Kero, J.; Schaub, A.; Wufka, C.; Blaukat, A.; Pfeffer, K.; Offermanns, S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect Nat. Med. 2003, 9, 352-355
55. Fang, Y.; Li, G.; Ferrie, A. M. Non-invasive optical biosensor for assaying endogenous G protein-coupled receptors in adherent cells J. Pharmacol. Toxicol. Methods 2007, 55, 314-322
56. Holdsworth, G.; Slocombe, P.; Hutchinson, G.; Milligan, G. Analysis of endogenous S1P and LPA receptor expression in CHO-K1 cells Gene 2005, 350, 59-63
57. Iredale, P. A.; Hill, S. J. Increases in intracellular calcium via activation of an endogenous P2-purinoceptor in cultured CHO-K1 cells Br. J. Pharmacol. 1993, 110, 1305-1310
58. Hoffman, B. B.; Lefkowitz, R. J. Radioligand binding studies of adrenergic receptors: new insights into molecular and physiological regulation Annu. Rev. Pharmacol. Toxicol. 1980, 20, 581-608
59. Arrang, J. M.; Roy, J.; Morgat, J. L.; Schunack, W.; Schwartz, J. C. Histamine H3 receptor binding sites in rat brain membranes: modulations by guanine nucleotides and divalent cations Eur. J. Pharmacol. 1990, 188, 219-227
60. Tsai, B. S.; Lefkowitz, R. J. Agonist-specific effects of monovalent and divalent cations on adenylate cyclase-coupled alpha adrenergic receptors in rabbit platelets Mol. Pharmacol. 1978, 14, 540-548
61. Puttfarcken, P.; Werling, L. L.; Brown, S. R.; Cote, T. E.; Cox, B. M. Sodium regulation of agonist binding at opioid receptors. I. Effects of sodium replacement on binding at mu- and delta-type receptors in 7315c and NG108-15 cells and cell membranes Mol. Pharmacol. 1986, 30, 81-89
62. Liu, W.; Chun, E.; Thompson, A. A.; Chubukov, P.; Xu, F.; Katritch, V.; Han, G. W.; Roth, C. B.; Heitman, L. H.; IJzerman, A. P.; Cherezov, V.; Stevens, R. C. Structural basis for allosteric regulation of GPCRs by sodium ions Science 2012, 337, 232-236
63. Bertarelli, D. C.; Diekmann, M.; Hayallah, A. M.; Rusing, D.; Iqbal, J.; Preiss, B.; Verspohl, E. J.; Müller, C. E. Characterization of human and rodent native and recombinant adenosine A(2B) receptors by radioligand binding studies Purinergic Signalling 2006, 2, 559-571
64. Drabczynska, A.; Yuzlenko, O.; Köse, M.; Paskaleva, M.; Schiedel, A. C.; Karolak-Wojciechowska, J.; Handzlik, J.; Karcz, T.; Kuder, K.; Müller, C. E.; Kiec-Kononowicz, K. Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones Eur. J. Med. Chem. 2011, 46, 3590-3607
65. Charlton, S. J. Agonist efficacy and receptor desensitization: from partial truths to a fuller picture Br. J. Pharmacol. 2009, 158, 165-168
66. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
67. Edwards, M. P.; Price, D. A. Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks Annu. Rep. Med. Chem. 2010, 45, 380-391
68. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997-10002
69. Thimm, D.; Knospe, M.; Abdelrahman, A.; Moutinho, M.; Alsdorf, B. A. A.; von Kügelgen, I.; Schiedel, A. C.; Müller, C. E. Characterization of new G protein-coupled adenine receptors in mouse and hamster Purinergic Signalling 2013, 10.1007/s11302-013-9360-9
70. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent J. Biol. Chem. 1951, 193, 265-275